Skip to Main Content

Paper Details

Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Nat Med
74
2020
LMD, Patients, breast cancer, hyperglycemia, leptomeningeal carcinomatosis, leptomeningeal dissemination of disease, lung cancer, metastatic cancer, nausea, ovarian cancer, patients, pembrolizumab, solid tumor malignancies, vomiting
Author NameAffiliation
Priscilla K BrastianosMassachusetts General Hospital, Harvard Medical School
Sara M TolaneyDana-Farber Cancer Institute, Harvard Medical School
Nancy U LinDana-Farber Cancer Institute, Harvard Medical School
Nancy WangMassachusetts General Hospital, Harvard Medical School
Ian E KropDana-Farber Cancer Institute, Harvard Medical School
Brian V NahedMassachusetts General Hospital, Harvard Medical School
Tracy T BatchelorMassachusetts General Hospital, Harvard Medical School
Tracy T BatchelorMassachusetts General Hospital, Harvard Medical School
Helen A ShihMassachusetts General Hospital, Harvard Medical School
Scott L CarterDana-Farber Cancer Institute, Harvard Medical School
  • 1 - 10

Datasets

Release 1.2